Telix Gets Second FDA Rejection For Kidney Cancer Drug

All NewsAugust 28, 2025

FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Telix Gets Second FDA Rejection For Kidney Cancer Drug

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Amazon has a 4-drawer wood desk organizer that looks like an antique store find for $36

Walmart is selling a retro-chic entertainment unit with 6 storage shelves on sale for $188

Democrat triumph offers China ‘window to catch up’ on AI

Tech’s teetering towers

What Democrats must do now